Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors

Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8.
No abstract available

Keywords: ABT-199; CD20 antibodies; chronic lymphocytic leukemia; kinase inhibitors; resistance.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
  • Drug Resistance, Neoplasm*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Rituximab / therapeutic use*
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*
  • Tumor Microenvironment / drug effects*

Substances

  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Rituximab
  • venetoclax